Ablatus Therapeutics is developing Bimodal Electric Tissue Ablation (BETA), an innovative improvement over existing tissue ablation techniques. The company aims to offer greater clinical options and to improve patient outcomes. On 30 June 2021 it received an £85,000 investment from Turquoise for the Low Carbon Innovation Fund 2. That contribution is part of an overall funding round the article states could reach £1.5 million. Turquoise is described in the article as a UK merchant bank specialising in energy, environment and efficiency. The article does not disclose further financial terms, instruments or operating metrics. Ablatus Therapeutics is commercialising a bimodal electric tissue ablation (BETA) technology that advances conventional radiofrequency ablation (RFA) by adding DC current to the needle alongside AC. BETA attracts moisture and reduces charring and dehydration, which the article says contributed to recurrence rates of almost 50% with previous methods. The company reports BETA improves ablation zone size and has the potential to treat tumours previously considered untreatable. The technique was developed at the Norfolk and Norwich Hospital, which retains a significant equity stake in the business and whose spinout this is. Ablatus intends to use the recently raised capital to support development of its product for treating cancer patients. In May the company closed a £500,000 investment round to advance its clinical and commercial development efforts.

Total raised

$118M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2021